Stock Market News1 week MRK’s Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study Zacks
The KEYLYNK-001 study evaluating Merck’s Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
X1 day Merck Ends Development of Two Experimental Cancer Drugs Zacks
X2 days CHMP Endorses Merck’s Kidney Cancer Drug for Two Indications Zacks
X6 days Merck (MRK) Ascends While Market Falls: Some Facts to Note Zacks
X7 days Merck (MRK) Stock Sinks As Market Gains: Here’s Why Zacks
X2 weeks Pharma Stock Roundup: LLY’s Zepbound Success, FDA Updates for MRK, JNJ Zacks
X2 weeks Merck & Co. Inc. (MRK) Citi’s 2024 Global Healthcare Conference (Transcript) Seeking Alpha
X2 weeks Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It Zacks
X2 weeks Merck’s ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC Zacks
X2 weeks Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript) Seeking Alpha
X3 weeks Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success Zacks
X4 weeks Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know Zacks
X4 weeks Top Analyst Reports for Broadcom, Merck & Qualcomm Zacks
X4 weeks Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference Seeking Alpha
X4 weeks Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma Zacks
X1 month Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy Zacks
X1 month Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript) Seeking Alpha
X2 months Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY’s Q3 Earnings in Focus Zacks
X2 months Merck & Co., Inc. (NYSE:MRK) Trading Down 2.9% – Here’s Why MarketBeat
X2 months Merck Q3 Earnings & Sales Top, Stock Down on Lowered ’24 View Zacks
X2 months Merck (MRK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks
X2 months Merck & Co., Inc. (NYSE:MRK) Trading Down 0.1% – Should You Sell? MarketBeat
X2 months Merck & Co., Inc. (NYSE:MRK) Trading Up 0.2% – What’s Next? MarketBeat
X2 months Dumont & Blake Investment Advisors LLC Sells 5,026 Shares of Merck & Co., Inc. (NYSE:MRK) MarketBeat
X2 months Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock? Zacks
X2 months Merck & Co., Inc. (NYSE:MRK) Trading Down 0.2% – Time to Sell? MarketBeat
X2 months Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know Zacks
X2 months Marks Electrical Group (LON:MRK) Reaches New 1-Year Low – Should You Sell? MarketBeat
X2 months Narwhal Capital Management Buys 15,510 Shares of Merck & Co., Inc. (NYSE:MRK) MarketBeat
X2 months Merck (MRK) Advances While Market Declines: Some Information for Investors Zacks
X2 months Zacks Research Predicts Lower Earnings for Merck & Co., Inc. MarketBeat
X2 months Merck & Co., Inc. (NYSE:MRK) Shares Bought by Vest Financial LLC MarketBeat
X2 months Top Research Reports for Visa, Netflix & Merck Zacks
X2 months Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold? Zacks
X2 months Gilead, MRK Report Data From Investigational Combination Study for HIV Zacks
X2 months Corundum Group Inc. Sells 6,325 Shares of Merck & Co., Inc. (NYSE:MRK) MarketBeat
X2 months Creative Planning Has $95.67 Million Position in Merck & Co., Inc. (NYSE:MRK) MarketBeat
XThe Stock Market News
TheStockMarketNews.com is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live trading analysis, opinions and forecasts on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds, rates and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.